When combined, they may increase the risk of hypoglycemia (low blood sugar)
Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
In recent years, a variety of studies have been conducted on the pharmacokinetics of semaglutide, including pharmacokinetics in healthy, pharmacokinetics in diseased, and the effects of drugdrug interactions and drugfood interactions on the pharmacokinetics of semaglutide in humans
Chemical Stability and Potency Over time, the chemical bonds in the semaglutide molecule begin to break down
Semaglutide targets the GLP-1 pathway, while tirzepatide activates both GLP-1 and GIP receptors, creating a dual-hormone effect that may influence blood sugar, satiety, and fat metabolism more comprehensively